← Back to Search

Hormone Therapy

Melatonin for Sleep Wake Disorders

Phase < 1
Recruiting
Led By Lauren Dunn, MD PHD
Research Sponsored by University of Virginia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Current use of sleep aids
History of transplant on immunosuppression therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Summary

This trial will study how melatonin affects sleep quality and quantity for doctors on night shift to help improve their performance.

Who is the study for?
This trial is for resident trainees in anesthesiology, general surgery, obstetrics and gynecology, general medicine, or pediatrics at the University of Virginia. Eligible participants are those in their first five years post-graduation who aren't using sleep aids or have a history of certain medical conditions like bleeding disorders, depression, high blood pressure, seizures, or are pregnant.Check my eligibility
What is being tested?
The study tests if melatonin improves sleep quantity and quality among residents working night shifts compared to a placebo. It's a double-blinded randomized control trial meaning neither the researchers nor participants know who receives melatonin or the inactive substance (placebo).See study design
What are the potential side effects?
Melatonin may cause side effects such as morning grogginess, vivid dreams or nightmares. Some people might also experience small changes in blood pressure and body temperature.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently using medication to help me sleep.
Select...
I have had a transplant and am on medication to suppress my immune system.
Select...
I have been diagnosed with a sleep disorder.
Select...
I have a bleeding disorder.
Select...
I have been diagnosed with depression.
Select...
I have high blood pressure.
Select...
I have a seizure disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total Sleep Time (TST)
Secondary outcome measures
Deep Sleep
Latency to Persistent Sleep (LPS)
Light Sleep
+3 more
Other outcome measures
Epworth Sleepiness Scale

Side effects data

From 2014 Phase 2 trial • 40 Patients • NCT01114373
42%
Fatigue
39%
Early Morning Wakening
36%
Daytime drowsiness
11%
Weakness
11%
Dizziness
11%
Nausea
11%
Blurred vision
100%
80%
60%
40%
20%
0%
Study treatment Arm
Melatonin
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Melatonin groupExperimental Treatment1 Intervention
These subjects will receive melatonin
Group II: Placebo groupPlacebo Group1 Intervention
These subjects will receive placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Melatonin
2014
Completed Phase 4
~1150

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Circadian Rhythm Disorder include melatonin and light therapy. Melatonin works by signaling to the body that it is time to sleep, helping to realign the circadian rhythm and increase sleep duration. Light therapy involves exposure to bright light at specific times to shift the circadian rhythm earlier or later, depending on the timing of the light exposure. These treatments are essential for correcting the misalignment of the internal body clock with the external environment, thereby improving sleep quality and overall functioning in patients with Circadian Rhythm Disorder.
The circadian basis of winter depression.

Find a Location

Who is running the clinical trial?

University of VirginiaLead Sponsor
761 Previous Clinical Trials
1,255,988 Total Patients Enrolled
Lauren Dunn, MD PHDPrincipal InvestigatorUniversity of Virginia

Media Library

Melatonin (Hormone Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05701969 — Phase < 1
Circadian Rhythm Disorder Research Study Groups: Melatonin group, Placebo group
Circadian Rhythm Disorder Clinical Trial 2023: Melatonin Highlights & Side Effects. Trial Name: NCT05701969 — Phase < 1
Melatonin (Hormone Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05701969 — Phase < 1
~16 spots leftby Jul 2025